PARP1 and glioblastoma: One bioinformatic analysis showed that it could be used as a biomarker in glioblastoma progression, while another study revealed that TRAF3IP2-AS1 propelled the development of a specific type of renal cancer (NONO-TFE3 translocation type) via PTEN downregulation and PARP1 m6A stimulation [56,57].